Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Nanjing Leads Biolabs Co., Ltd. Class H ( (HK:9887) ) has shared an announcement.
Nanjing Leads Biolabs Co., Ltd. has announced the successful dosing of the first patient in a Phase Ib/II clinical trial for Opamtistomig, a bispecific antibody targeting PD-L1 and 4-1BB, for advanced melanoma treatment. This development highlights the company’s progress in cancer treatment innovation, potentially enhancing its market position and offering new treatment options for stakeholders.
The most recent analyst rating on (HK:9887) stock is a Buy with a HK$80.27 price target. To see the full list of analyst forecasts on Nanjing Leads Biolabs Co., Ltd. Class H stock, see the HK:9887 Stock Forecast page.
More about Nanjing Leads Biolabs Co., Ltd. Class H
Nanjing Leads Biolabs Co., Ltd. is a biotechnology company based in China, focusing on the development of innovative cancer treatments. The company specializes in bispecific antibodies, with a market focus on advanced cancer therapies.
Average Trading Volume: 2,318,835
For an in-depth examination of 9887 stock, go to TipRanks’ Overview page.